# EDGAR Filing Document

**Accession Number:** 0001653087
**File Stem:** 0000950170-25-091669
**Filing Date:** 2025-6
**Character Count:** 11660
**Document Hash:** 40dc2cc8bbdc402ce4005229829df53c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-091669.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0000950170-25-091669

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250620

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Wong-Sarad Grace
- **CENTRAL INDEX KEY:** 0002074667

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38792
- **FILM NUMBER:** 251092744

**MAIL ADDRESS:**
- **STREET 1:** C/O ALECTOR, INC.
- **STREET 2:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alector, Inc.
- **CENTRAL INDEX KEY:** 0001653087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822933343
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-231-5660

**MAIL ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alector LLC
- **DATE OF NAME CHANGE:** 20150915

## Ex-24

**POWER OF ATTORNEY**

The undersigned hereby makes, constitutes and appoints Arnon Rosenthal, Danielle Pasqualone, Neil Berkley, Cameron Hagen and Bowen Shi, and each of them, as the undersigned's true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 13 Section 16(a) of the Securities Exchange Act of 1934 (the "Securities Act") or any rule or regulation of the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC, Alector, Inc. (the "Company"), and/or any national securities exchange on which the Company's securities are listed any and all reports (including amendments thereto) the undersigned is required to file with the SEC, or which such Attorney-in-Fact shall in his or her discretion determine to be required or advisable pursuant to Section 13 or Section 16 of the Securities Act and the rules and regulations promulgated thereunder, or pursuant to Rule 144 under the Securities Act ("Rule 144"), or any successor laws and regulations, with respect to any security of the Company, including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for

------

any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.

This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an employee and/or director of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of June, 2025.

Signature: /s/ Grace Wong-Sarad

Print Name: Grace Wong-Sarad

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Wong-Sarad Grace<br><sub>(Last) (First) (Middle)</sub><br>C/O ALECTOR, INC.<br>131 OYSTER POINT BLVD, SUITE 600<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Alector, Inc. [ ALEC ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-20 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Principal Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 109358<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2029-08-31 | Common Stock | 20000 | $16.46 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2029-11-05 | Common Stock | 13842 | $17.15 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2030-09-30 | Common Stock | 20454 | $10.24 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2030-11-30 | Common Stock | 10228 | $13.56 | D |  |
| Employee Stock Option (right to buy) | <sup>(3)</sup> | 2031-09-30 | Common Stock | 11552 | $23.70 | D |  |
| Employee Stock Option (right to buy) | <sup>(4)</sup> | 2032-09-30 | Common Stock | 11309 | $9.46 | D |  |
| Employee Stock Option (right to buy) | <sup>(5)</sup> | 2035-05-15 | Common Stock | 2845 | $1.105 | D |  |

---

### Footnotes:

(1) Of the reported shares, 60,841 are represented by restricted stock units, or RSUs, which vest as follows: (i) 3,148 RSUs vest in two equal quarterly installments beginning on September 1, 2025; (ii) 6,252 RSUs vest in three equal quarterly installments beginning on September 1, 2025; (iii) 3,334 RSUs vest in four equal quarterly installments beginning on September 1, 2025; (iv) 15,973 RSUs vest in five equal quarterly installments beginning on September 1, 2025; and (v) 32,134 RSUs vest in nine equal quarterly installments beginning on September 1, 2025.

(2) The shares subject to the option are fully vested and immediately exercisable.

(3) Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2021.

(4) Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2022.

(5) Shares subject to the option vest in 12 equal monthly installments beginning on June 1, 2025.

**Signature:** /s/ Grace Wong-Sarad  
**Date:** 2025-06-30

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**